A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Sponsor

Chordia Therapeutics, Inc. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05732103

Collaborator

Theradex (Industry)

170

Enrollment

Locations

Arms

Anticipated Duration (Months)

Patients Per Site

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS).

The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by a confirmatory phase 1 expansion cohort where an additional approximately 10 patients will be treated with CTX-712 at the RP2D to gain further confidence in the selected dose level. After RP2D is determined, Drug-Drug-Interaction cohorts will be started.

The phase 2 part of the study will commence after the RP2D has been identified and confirmed and will evaluate therapeutic activity in R/R AML or R/R HR-MDS, in addition to confirmation of the safety profile.

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia Myelodysplastic Syndromes	Drug: CTX-712	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

170 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Anticipated Study Start Date :

Apr 1, 2023

Anticipated Primary Completion Date :

Dec 1, 2026

Anticipated Study Completion Date :

Dec 1, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dose Escalation Cohort Drug: CTX-712 administered at 20 mg, 40 mg, 80 mg, 100 mg, 140 mg weekly	Drug: CTX-712 CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
Experimental: Dose Expansion Cohort Drug: CTX-712 administered at a dose to be determined from the data of dose escalation cohort	Drug: CTX-712 CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
Experimental: Phase 2 CTX-712 administered at the recommended dose by the expansion cohort	Drug: CTX-712 CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Arm

Intervention/Treatment

Experimental: Dose Escalation Cohort

Drug: CTX-712 administered at 20 mg, 40 mg, 80 mg, 100 mg, 140 mg weekly

Drug: CTX-712

CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Experimental: Dose Expansion Cohort

Drug: CTX-712 administered at a dose to be determined from the data of dose escalation cohort

Drug: CTX-712

CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Experimental: Phase 2

CTX-712 administered at the recommended dose by the expansion cohort

Drug: CTX-712

CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Outcome Measures

Primary Outcome Measures

Phase 1: Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to CTX-712. [Adverse events are collected from time of informed consent through 28 days after last dose of CTX-712.]
Phase 1: The maximum tolerated dose MTD. [Dose-limiting toxicities are collected during the first treatment cycle (28 days).]
MTD is the dose producing <33% of dose-limiting toxicities.
Phase 2: Complete remission rate, defined as the proportion of patients who achieve complete remission. [Measured from date of first dose to 28 days after last dose of CTX-712.]

Secondary Outcome Measures

Phase 1 and 2: Objective response rate, defined as the proportion of patients achieving a response. [Measured from date of first dose to 28 days after last dose of CTX-712.]
For AML: CR, CRi, PR, MLFS. For MDS: CR, PR, mCR, HI.
Phase 1 and 2: Duration of response. [Measure from documentation of tumor response to disease progression or death from any cause, whichever occurs first, assessed up to 24 months.]
Phase 1 and 2: Progression-free survival. [Measured from the date of initiating study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months.]
Phase 1 and 2: Overall survival. [Measured from the date of initiating study treatment to the date of death from any cause, assessed up to 36 months.]
Phase 1 and 2: Proportion of patients who transition to hematopoietic stem cell transplantation (HSCT). [Measured from the date of the last administration of CTX-712 until HSCT, or one year from the date of the start of administration of CTX-712.]
Phase 1: Maximum observed plasma concentration (Cmax) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed. [Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).]
Phase 1: Concentration before dose at steady state (Ctrough) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed. [Pharmacokinetic evaluation performed in treatment Cycles 1, 2 and 4 (cycle duration is 28 days).]
Phase 1: Area under the plasma concentration time curve (AUC) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed. [Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).]
Phase 1: Volume of distribution (Vd) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed. [Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).]
Phase 1: Elimination half-life of plasma concentration of CTX-712 at terminal phase (T1/2). Plasma samples for PK analyses will be collected at predetermined time points and analyzed. [Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).]
Phase 1: Clearance (CL) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed. [Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).]
Phase 1: Measurement of the change in RNA splicing by CTX-712 in peripheral blood samples as pharmacodynamic markers. Peripheral blood samples for PD analyses will be collected at predetermined time points and analyzed. [Pharmacodynamic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

Age ≥18 years.
Diagnosis of AML, HR-MDS, or high marrow blast MDS/MPN (including CMML).
Prior treatment history must include 1-4 prior lines of therapy.
Adequate organ function evidenced by the following laboratory values:

Creatinine clearance (CL) ≥60 mL/min Total serum bilirubin < 1.5 × upper limit of normal (ULN) Alanine aminotransferase (ALT) Aspartate aminotransferase(AST) < 2.5 × ULN White blood cell count at the time of the first dose <10 k/μL

Eastern Cooperative Oncology Group performance status ≤2.
Female patients of childbearing potential must have a negative pregnancy test within 7 days before study treatment initiation and if sexually active, agree to use a highly effective form of contraception throughout their participation during study treatment and up to 4 months after the last dose of study drug
Male patients with female partners of childbearing potential must, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant.

Exclusion criteria:

Diagnosis of acute promyelocytic leukemia.
Isolated extramedullary relapse (phase 2 only).
Active central nervous system (CNS) leukemia.
History of other malignancy.
Any of the following cardiopulmonary abnormalities:
Myocardial infarction within six months prior to registration.
New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction < 50%.
A history of familial long QT syndrome.
Symptomatic atrial or ventricular arrhythmias not controlled by medications.
QTcF ≥ 470 msec calculated according to institutional guidelines, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.
Known moderate to severe and clinically significant chronic obstructive pulmonary disease, interstitial lung disease and/or pulmonary fibrosis (e.g., requiring home oxygen therapy).
Pregnancy and/or lactation.
Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of CTX-712.
History of allogeneic organ transplantation (excluding cornea).
History of allogenic hematopoietic stem cell transplantation within 6 months of planned study treatment initiation and/or graft-versus host disease grade ≥ 1 following allogenic hematopoietic stem cell transplantation.
History of or chimeric antigen receptor T-cell therapy or other modified T cell therapy.
Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus, hepatitis C virus, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness. Infections controlled with oral anti-infective agents, including prophylactic treatments, are allowed. Patient must be viral load negative.
Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic Comprehensive Cancer Center	Rochester	Minnesota	United States	55905
2	The University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030